<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126083</url>
  </required_header>
  <id_info>
    <org_study_id>19-0002763</org_study_id>
    <nct_id>NCT04126083</nct_id>
  </id_info>
  <brief_title>Lofexidine for Adults Undergoing Lumbar Spine Surgery</brief_title>
  <official_title>Lofexidine for Rapid Pre-Operative Opioid Tapering in Adults Undergoing Lumbar Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US WorldMeds LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to investigate the effects of lofexidine in adults undergoing opioid&#xD;
      tapering prior to elective lumbar spine surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical trial, an open label design will be used to facilitate opioid tapering&#xD;
      during a 12-day period prior to elective spine surgery. The primary outcome measure of this&#xD;
      study is the number of patients who achieve a 50% reduction in daily opioid dose at day 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid tapering</measure>
    <time_frame>12 days</time_frame>
    <description>The proportion of patients who discontinue opioid use.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Opioid Withdrawal</condition>
  <arm_group>
    <arm_group_label>Lofexidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive lofexidine 0.54 mg 4 times daily and the baseline opioid dose will be reduced by 10% daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine Oral Tablet</intervention_name>
    <description>Open label trial of lofexidine to facilitate opioid tapering prior to elective lumbar spine surgery.</description>
    <arm_group_label>Lofexidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 70 years.&#xD;
&#xD;
          2. Chronic lumbar spine pain for â‰¥ 3 months duration.&#xD;
&#xD;
          3. Scheduled for elective lumbar spine surgery.&#xD;
&#xD;
          4. Daily morphine equivalent dose between 50 mg and 200 mg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cancer-related pain.&#xD;
&#xD;
          2. Medical or surgical conditions that could be adversely impacted by opioid tapering or&#xD;
             use of lofexidine including, but not exclusively limited to, cardiac disease,&#xD;
             inflammatory bowel disease, renal or hepatic impairment, vascular disease, and history&#xD;
             of anaphylaxis. Patients may be excluded for other comorbid medical or surgical&#xD;
             conditions based on the physician investigator's discretion.&#xD;
&#xD;
          3. History of schizophrenia or other chronic psychiatric disorder that could be adversely&#xD;
             impacted by opioid tapering or use of lofexidine. Patients may be excluded for other&#xD;
             comorbid mental health conditions based on the physician investigator's discretion.&#xD;
&#xD;
          4. Neurological condition that impair functioning in an ambulatory setting or could be&#xD;
             adversely impacted by opioid tapering or use of lofexidine including, but not&#xD;
             exclusively limited to, Parkinson's disease, amyotrophic lateral sclerosis, or a&#xD;
             dementing illness. Patients may be excluded for other neurological conditions based on&#xD;
             the physician investigator's discretion.&#xD;
&#xD;
          5. Active substance abuse disorder.&#xD;
&#xD;
          6. Inability to function in an ambulatory care setting due to severe deconditioning&#xD;
             requiring use of supportive gait aids including a cane or walker. Patients may be&#xD;
             excluded for other functional problems based on the physician investigator's&#xD;
             discretion.&#xD;
&#xD;
          7. History of adverse effects attributed to opioid tapering or lofexidine use.&#xD;
&#xD;
          8. Use of medications from drug classes known to have adverse interactions with&#xD;
             lofexidine including, but not exclusively limited to, beta-blockers, calcium channel&#xD;
             blockers, alpha 1 and 2 receptor antagonists, tricyclic antidepressants,&#xD;
             benzodiazepines, and selective serotonin reuptake inhibitors. Patients may be excluded&#xD;
             for use of other medications based on the physician investigator's and research&#xD;
             pharmacy's discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William M Hooten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>Fishman M, Tirado C, Alam D, Gullo K, Clinch T, Gorodetzky CW; CLEEN-SLATE Team. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial. J Addict Med. 2019 May/Jun;13(3):169-176. doi: 10.1097/ADM.0000000000000474.</citation>
    <PMID>30531234</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>W. Michael Hooten</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Opioid tapering</keyword>
  <keyword>Spine surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lofexidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Individual participant data plan is undetermined.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

